GSE182150 KIT LSD1 MYC inhibition 4 v 5 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE182150_KIT_LSD1_MYC inhibition_4_v_5_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE182150_KIT_LSD1_MYC inhibition_4_v_5_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE182150_KIT_LSD1_MYC inhibition_4_v_5_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE182150_KIT_LSD1_MYC inhibition_4_v_5_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

MSL complex subunit 3B

Gene

colony stimulating factor 2 receptor subunit alpha

Gene

dehydrogenase/reductase X-linked

Gene

taxilin gamma Y-linked (pseudogene)

Gene

long intergenic non-protein coding RNA 667

Gene

XG Y-linked 2 (pseudogene)

Gene

MIR9-3 host gene

Gene

OTUD6B antisense RNA 1

Gene

long intergenic non-protein coding RNA 865

Gene

HOXB cluster antisense RNA 1

  • Gene

    MSL complex subunit 3B


  • Gene

    colony stimulating factor 2 receptor subunit alpha


  • Gene

    dehydrogenase/reductase X-linked


  • Gene

    taxilin gamma Y-linked (pseudogene)


  • Gene

    long intergenic non-protein coding RNA 667


  • Gene

    XG Y-linked 2 (pseudogene)



  • Gene

    OTUD6B antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 865


  • Gene

    HOXB cluster antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.